Swiss pharmaceutical giant Roche (SWX: ROG) has presented compelling long-term efficacy data for its selective immunosuppressant Ocrevus (ocrelizumab) in the treatment of multiple sclerosis (MS). The 10-year results from a Phase III extension study provide significant insights into the drug’s sustained impact on patients with relapsing and primary progressive forms of the disease.
Long-Term Efficacy in Relapsing MS Patients
According to the study, 77% of patients with relapsing MS were free from disability progression after a decade of treatment with Ocrevus. This figure is particularly noteworthy, as it highlights the drug’s effectiveness in managing the disease’s progression over an extended period. Additionally, 92% of these patients continued to walk unassisted, indicating a preservation of physical function.
Primary Progressive MS Outcomes
In the primary progressive MS cohort, 36% of patients experienced no disability progression, and 80% were able to walk unassisted. These results, while lower than those for relapsing MS, still demonstrate the potential benefits of Ocrevus in a patient population that typically has fewer treatment options.
Consistent Safety Profile Over Decade
Roche’s Ocrevus has maintained a consistent safety profile over the 10-year study period, which is crucial for long-term treatment plans. Moreover, the drug’s safety among pregnant women, with no increased risk in adverse pregnancy and infant outcomes, adds to its favorable profile.
Conclusion
The decade-long data from Roche’s study reinforces Ocrevus’s position as a viable treatment option for multiple sclerosis. Its sustained efficacy and consistent safety profile make it an important consideration for both patients and healthcare providers managing this chronic condition.-Fineline Info & Tech
